A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.
Yi Mo, Julie Stromswold, Kimberly Wilson, Daniel Holder, Cyrille Sur, Omar Laterza, Mary J Savage, Arie Struyk, Philip Scheltens, Charlotte E Teunissen, James Burke, S Lance Macaulay, Geir Bråthen, Sigrid Botne Sando, Linda R White, Christy Weiss, Arturo Cowes, Michele M Bush, Ganga DeSilva, David G Darby Show all
Alzheimer's & dementia (Amsterdam, Netherlands) | Published : 2017
INTRODUCTION: Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development of Alzheimer's brain pathology. Robust tau and Aβ42 immunoassays were developed to establish a tau/Aβ42 cutoff distinguishing mild-to-moderate Alzheimer's disease (AD) subjects from healthy elderly control (HC) subjects. METHODS: A CSF tau/Aβ42 cutoff criteria was chosen, which distinguished the groups and maximized concordance with amyloid PET. Performance was assessed using an independent validation cohort. RESULTS: A tau/Aβ42 = 0.215 cutoff provided 94.8% sensitivity and 77.7% specificity. Concordance with PET visual reads was estimated at 86.9% in a ∼50% PET positive population. In the valid..View full abstract